Answers are grounded in this paper and cite their sources.
Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of breast cancer, with the triple-negative variant (TN-MpBC) being particularly resistant to standard systemic therapies and associated with poor outcomes. We present the case of a 48-year-old African American female diagnosed with TN-MpBC, incidentally identified during cardiac evaluation for sarcoidosis. Imaging and biopsy revealed a 5.8 cm high-grade tumor with a Ki-67 index above 30%. The patient was treated with the KEYNOTE-522 regimen, which includes neoadjuvant chemotherapy (NAC) (paclitaxel, carboplatin, doxorubicin, and cyclophosphamide) and pembrolizumab immunotherapy. Post-treatment imaging demonstrated substantial tumor regression, and subsequent bilateral mastectomy confirmed a complete pathological response with no residual malignancy. She is currently undergoing adjuvant pembrolizumab and proton radiation therapy. Given the historically poor response of TN-MpBC to chemotherapy alone, this case illustrates the promising role of immunotherapy, particularly in programmed death-ligand 1 (PD-L1)-expressing tumors. It supports emerging evidence that chemoimmunotherapy combinations such as KEYNOTE-522 may improve prognosis in TN-MpBC, emphasizing the need for continued investigation into targeted therapeutic strategies for this challenging breast cancer subtype.
No takes yet. Share an insight, caveat, or question.
Nimmagadda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: